Notice of Pre-AIA or AIA Status
The present application is being examined under the pre-AIA first to invent provisions.
Priority
This application is a continuation application of USSN 18/391,876 filed December 21, 2023, which was a continuation application of USSN 17/734,331 filed May 2, 2022, which was a continuation application of USSN 16/662,126 filed October 24, 2019 now US Patent 11,357,778, which was a continuation application of USSN 15/872,307 filed January 16, 2018, which was a continuation application of USSN 14/844,041 filed September 3, 2015 now US Patent 9,931,341, which was a continuation application of USSN 14/364,320 filed June 11, 2014 which was a national stage filing under 35 USC 371 of PCT/EP2012/075294 filed December 12, 2012, which claimed priority to PCT/IB2011/003253 filed December 12, 2011
Claims Status
Claims 1 and 2 are pending and under examination.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
Claims 1 and 2 are rejected under pre-AIA 35 U.S.C. 102(a) as being anticipated by
Guagnano, Journal of American Chemical Society, 27 October 2011, vol. 54, No. 20, pages 7066-7083 (copy previously can be found in copending Application No. 14/364,320).
Guagnano teaches oral administration of an effective amount of 1h (NVP-BGJ-398) which is structurally identical to the compound recited in claims 1 and 2, to tumor-bearing rats at doses 5, 10, and 15 mg/kg. See pages 7072, right column, and Figure 7. Guagnano reports that administration of the compound produced antitumor activity, including nearly complete tumor stasis at 5 mg/kg and tumor regression at higher doses. See pages 7071-7073.
Accordingly, Guagnano expressly teaches administration of a therapeutically effective amount of the claimed compound to a mammalian subject in need of treatment.
Moreover, the instant specification identifies BGJ-398 as being administered at about 1-10 mg/kg, preferably 2-8 mg/kg, and more preferably about 4-6 mg/kg. Thus, the 5 mg/kg dose disclosed by Guagnano falls squarely within the specification’s more preferred therapeutic effective dosage range. The foregoing further supports that Guagnano discloses the positively recited administration step, including administration of a therapeutically effective amount of the claimed compound.
Accordingly, the recitations of “thereby treating achondroplasia” (claim 1) and “thereby treating hypochondroplasia” (claim 2) are interpreted as statements of the intended therapeutic results of the positively recited administration step, rather than requiring additional affirmative method steps. Under the broadest reasonable interpretation, these clauses do not further limit the claimed administration step. See Bristol-Meyers Squibb Co. v. Ben Venue Laboratories, 246 F.3d 1368 (Fed. Cir. 2001).
To the extent Guagnano discloses administration of a therapeutically effective amount to a subject in need thereof, the reference teaches the positively recited administering limitations. Accordingly, the disease-specific intended results do not independently distinguish the claimed methods form the prior art.
Double Patenting
The non-statutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A non-statutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on non-statutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.
Claims 1 and 2 are rejected on the ground of non-statutory double patenting as being un-patentable over claim 1 of U.S. Patent No. 9,931,341 B2. Although the claims at issue are not identical, they are not patentably distinct from each other.
The U.S. patent claims teach a method for treating a FGFR3-related skeletal disease which comprises the step of administering a therapeutically effective amount of at least one antagonist of the FGFR3 tyrosine kinase receptor of formula
PNG
media_image1.png
121
294
media_image1.png
Greyscale
or a composition comprising such an antagonist, to a subject in need thereof, and treating the FGFR3-related skeletal disease in said subject, wherein the FGFR3-related skeletal disease is achondroplasia. The claims of the U.S. patent anticipate the instant claim.
Accordingly, the recitations of “treating hypochondroplasia” (claim 2). To the extent U.S. patent discloses administration of a therapeutically effective amount to a subject in need thereof, the reference teaches the positively recited administering limitations. Accordingly, the disease-specific intended results do not independently distinguish the claimed methods form the prior art.
Claims 1 and 2 are rejected on the ground of non-statutory double patenting as being un-patentable over claim 1 of U.S. Patent No. US11357778B2. Although the claims at issue are not identical, they are not patentably distinct from each other.
The U.S. patent claims teach a method for treating hypochondroplasia which comprises the step of administering a therapeutically effective amount of at least one antagonist of the FGFR3 tyrosine kinase receptor of formula
PNG
media_image1.png
121
294
media_image1.png
Greyscale
or a composition comprising such an antagonist to said subject. The claims of the U.S. patent anticipate the instant claim.
Regarding the recitations of “treating achondroplasia” (claim 1). To the extent U.S. patent discloses administration of a therapeutically effective amount to a subject in need thereof, the reference teaches the positively recited administering limitations. Accordingly, the disease-specific intended results do not independently distinguish the claimed methods form the prior art.
Conclusion
Claims 1 and 2 are not allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JEAN P CORNET whose telephone number is (571)270-7669. The examiner can normally be reached Monday-Thursday from 7.00am-5.30pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L Clark can be reached on 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JEAN P CORNET/Primary Examiner, Art Unit 1628